Please use this identifier to cite or link to this item: https://doi.org/10.3389/fonc.2021.700722
Title: Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
Authors: Lu, Yen-Shen
Wong, Andrea 
Kim, Hee-Jeong
Keywords: breast cancer
endocrine therapy
luteinizing hormone releasing hormone
ovarian function preservation
ovarian function suppression (OFS)
premenopausal
Issue Date: 14-Sep-2021
Publisher: Frontiers Media S.A.
Citation: Lu, Yen-Shen, Wong, Andrea, Kim, Hee-Jeong (2021-09-14). Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. Frontiers in Oncology 11 : 700722. ScholarBank@NUS Repository. https://doi.org/10.3389/fonc.2021.700722
Rights: Attribution 4.0 International
Abstract: Chemotherapy and endocrine therapies are mainstays of treatment for early and advanced hormone receptor-positive (HR+) breast cancer. In premenopausal women with HR+ tumors, the benefits of adding ovarian function suppression (OFS) to endocrine therapy have been debated. Consequently, for many years, tamoxifen monotherapy has been the standard of care for endocrine treatment in the adjuvant setting. Recent studies have, however, provided new evidence that, in some premenopausal patients, OFS in combination with tamoxifen or aromatase inhibitors (AIs) can significantly increase survival versus tamoxifen alone. Luteinizing hormone-releasing hormone agonists (LHRHa), including goserelin, triptorelin, and leuprorelin, achieve OFS through sustained suppression of the release of follicle-stimulating hormone and luteinizing hormone from the pituitary. In turn, this suppresses production and secretion of estradiol, an ovarian hormone that supports cancer cell growth, survival, and proliferation. In this review, we discuss the clinical evidence supporting the addition of LHRHa to adjuvant endocrine therapies, including tamoxifen and AIs, for premenopausal women with breast cancer. We also discuss the role of LHRHa use in combination with adjuvant chemotherapy to preserve ovarian function and fertility in young patients with breast cancer. Finally, we discuss important practical aspects of the use of LHRHa in breast cancer treatment, including side-effects, patient adherence to treatment, and the use of slow-release, long-acting drug formulations. © Copyright © 2021 Lu, Wong and Kim.
Source Title: Frontiers in Oncology
URI: https://scholarbank.nus.edu.sg/handle/10635/232401
ISSN: 2234-943X
DOI: 10.3389/fonc.2021.700722
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fonc_2021_700722.pdf2.55 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

4
checked on Nov 21, 2022

Page view(s)

10
checked on Nov 17, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons